Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Endometrial Adenocarcinoma 1Cystadenocarcinoma, Serous 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 2Taxes 1Neoadjuvant Therapy 1Letrozole 1Lapatinib 1Gonadotropin-Releasing Hormone 1Doxorubicin 1Cisplatin 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Inflammatory Breast Neoplasms × Taxes × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡